About ReBEC

The Brazilian Clinical Trials Registry (ReBEC) is an open-access virtual platform for registering experimental and non-experimental studies involving human beings conducted in Brazilian territory by Brazilian and foreign researchers. ReBEC is a joint project of the Ministry of Health (DECIT/MS), the Pan American Health Organization (PAHO), and the Oswaldo Cruz Foundation (FIOCRUZ). The Executive Committee of ReBEC is composed of the aforementioned institutions and the National Health Surveillance Agency (ANVISA). ReBEC is an important source of information for patients, healthcare professionals, researchers, companies, and research centers. Its support services feature generative artificial intelligence ReBEC@, the first artificial intelligence for clinical trial registration in the world. Learn more

Everything you need to know about ReBEC

Click to access the hotsite

Click to download the PDF version

Instructions for the Registrant

We recommend reading the Registrant's Manual.

1 - Register or log in and fill out the forms normally in Portuguese and English.
For English, if you experience any difficulty, use Google Translate
(or another free translation tool).
2 - Attach the mandatory ethics committee documentation and submit the form.
3 - Save the support number in your WhatsApp contacts. Send a message with your name and username.
It is not necessary or recommended to send your password. 
4 - A reviewer will respond to you. Choose your preferred communication mode:
chat, audio recordings, or scheduled voice call.
5 - Your form will be reviewed in both languages. Follow further instructions to complete approval.

Clinical Research Volunteer

Would you like to become a volunteer in a clinical trial registered in ReBEC?

Access our FAQ to find out how.

11/05/2026  |  Aaron Tallent  |  ASCO Connection

https://connection.asco.org/do/medicine-all-right-reasons-improving-u-s-veterans-enrollment-cancer-clinic-trials?referrer=https%3A%2F%2Fwww.google.com%2F 

Travel, multiple comorbidities, and strict eligibility criteria have led to low cancer clinical trial participation across the U.S., and that rate is even lower for military veterans.1 A pilot initiative through Florida Cancer Specialists & Research Institute (FCS), Sarah Cannon Research Institute (SCRI), and the U.S. Department of Veterans Affairs (VA) aims to expand access and increase veteran enrollment in clinical trials through a tailored approach designed to boost awareness and options.

“Fortunately, we do not have to recreate the wheel for U.S. veterans, but we need to make certain that the wheel that we do create includes them as well,” said 2026-2027 ASCO president Elizabeth A. Mittendorf, MD, PhD, MHCM, FASCO.

U.S. Veterans and Cancer
Approximately 56,000 U.S. veterans are diagnosed with cancer each year2; Dr. Mittendorf noted that they face unique challenges compared to other patients with cancer. For example, veterans have an increased risk for certain cancers and many have been exposed to environmental conditions that are specific to the military, such as Agent Orange in the Vietnam War and burn pits for waste in the Gulf War and wars in Iraq and Afghanistan.3

“That speaks to the challenges of risk assessment because we cannot do a direct comparison and assess our veterans in the exact same way we do others who have not had those exposures,” said Dr. Mittendorf.

Dr. Mittendorf has seen the experiences of many veterans firsthand. She accepted a U.S. Air Force scholarship…

11/06/2026  |  Open Access Government

https://www.openaccessgovernment.org/two-new-ebola-vaccines-are-expected-to-join-clinical-trials-in-the-dr-congo/216232/ 

Two new Ebola vaccine candidates designed to protect against the Bundibugyo strain of Ebola are set to join an ongoing clinical trial in the Democratic Republic of the Congo (DRC)

The World Health Organization (WHO) has recommended that both vaccines undergo further clinical testing as research into potential ways to prevent and treat the disease continues.

Two new vaccine candidates are recommended
The Ebola vaccine ChAdOx1, developed by the University of Oxford in partnership with the Serum Institute of India, and Moderna’s mRNA-1469.

Both Ebola vaccine candidates have been selected following a review of available early clinical and preclinical evidence by an independent WHO advisory group.

If they receive national approval, the vaccines will be added to the Tumaini clinical trial. This will be the first time vaccines specifically developed to protect against the Bundibugyo virus are tested during an active outbreak.

The DRC’s Institut National de Recherche Biomédicale is leading the trial, working alongside international research organisations and health partners.

How the Tumaini trial works
The Tumaini trial uses a ring-vaccination approach, which involves offering vaccines to people who have been in contact with confirmed Ebola patients.

Four vaccination rings have already been established, with several more being prepared. The study is designed to assess multiple vaccine candidates within one trial.

The existing vaccine, Ervebo, is also being evaluated to determine its effectiveness against the Bundibugyo…

11/06/2026 | Abigail Beaney | Clinical Trials Arena

https://www.clinicaltrialsarena.com/news/who-adds-two-more-ebola-vaccines-to-clinical-trial/ 

The WHO has approved the addition of the ChAdOx1 and mRNA-1469 to the Ebola trial.

The World Health Organization (WHO) will add two more Ebola vaccines to the ongoing Tumaini clinical trial.

The Phase II/III study (NCT07842107), which is being conducted in the Democratic Republic of the Congo (DRC), will now also evaluate ChAdOx1, developed by the University of Oxford with the Serum Institute of India, and Moderna’s mRNA-1469, which are specifically designed for the Bundibugyo virus, the virus responsible for the current outbreak.

The WHO’s independent Technical Advisory Group on Candidate Vaccines Prioritization recommended both vaccines for further clinical evaluation this week, based on available preclinical and early clinical evidence.

The companies were informed on Monday. The vaccine candidates will enter the trial following national approvals.

Dr Tedros Adhanom Ghebreyesus, WHO director-general, said: “The fact that these vaccines are ready to enter clinical trials is a testament to the power of science and partnership.”

“Vaccines alone will not end this outbreak, but they could become a powerful new tool for bringing it under control,” Adhanom Ghebreyesus added.

Tumaini is designed to test multiple vaccine candidates within a single trial using a ring-vaccination approach that enrols contacts of people with confirmed Bundibugyo virus disease.

It builds on an approach pioneered by WHO and its partners during the West Africa Ebola outbreak a decade ago, when a landmark trial in Guinea established the efficacy of MSD’s Ervebo against Ebola virus, also known as Zaire ebolavirus.

11/05/2026 | Ministério da Ciência, Tecnologia e Inovação

https://www.gov.br/mcti/pt-br/acompanhe-o-mcti/noticias/2026/11/pesquisas-do-cnpem-investigam-metastase-e-resposta-do-cancer-de-mama-a-tratamentos 

Studies using patient-derived cells, nanoparticles, and new technologies aim to understand the differences between tumors and contribute to more personalized treatments.

Why might patients with seemingly similar tumors respond differently to the same medications? How do breast cancer cells manage to reach the brain?

Researchers at the Brazilian Center for Research in Energy and Materials (CNPEM), in Campinas (São Paulo state), are investigating these questions through various approaches, seeking to expand knowledge about the disease and identify factors that influence treatment response.

The research focuses on the mechanisms of cancer and the identification of factors that affect how it responds to treatment. To this end, the team employs three-dimensional models cultured from patient samples, as well as nanoparticles and devices that integrate sensors with artificial intelligence techniques.

“Our research at CNPEM seeks to understand why breast tumors respond differently to treatments and how certain cells manage to spread to other organs,” explains researcher Sandra Dias.

How do cancer cells spread throughout the body?

Part of this research tracks cells that detach from the original tumor and enter the bloodstream. Some of these cells survive and reach other organs, contributing to the spread of the disease—a process known as metastasis.

Cyro Negrão is studying a strategy that uses nanoparticles to bring these circulating tumor cells into closer proximity with…

11/05/2026 | Gabriela Costa | Portal Afya

https://portal.afya.com.br/saude/oms-inclui-duas-novas-vacinas-contra-ebola-em-ensaio-clinico 

The World Health Organization (WHO) is expanding research into Ebola vaccines and investigating new therapies, with clinical results expected in the coming months.

On November 4, the World Health Organization (WHO) recommended the inclusion of two Ebola vaccine candidates in the "Tumaini" clinical trial in the Democratic Republic of the Congo. These vaccines were developed specifically to target the Bundibugyo virus—the strain responsible for the outbreak in the country—and will be incorporated into the study following national regulatory approvals.

The recommendation was made by independent experts convened by the WHO, following an analysis of preclinical evidence and initial clinical data. The investigation aims to determine the efficacy of these candidates during an active outbreak—a crucial step in establishing their potential to provide protection.

Tumaini clinical trial employs ring vaccination
The vaccines selected for evaluation are ChAdOx1, developed by the University of Oxford in partnership with the Serum Institute of India, and mRNA-1469, developed by Moderna. The Tumaini trial allows for the investigation of multiple vaccine candidates under a single protocol, utilizing a "ring vaccination" strategy among the contacts of individuals with a confirmed Bundibugyo infection.

The vaccine Ervebo is also being evaluated in the trial to determine its efficacy against the Bundibugyo strain. While its effectiveness against the Zaire species of the Ebola virus has already been established, this does not confirm protection against the specific strain involved in the current outbreak.

Four "vaccination…